Fractyl Health Highlights the Preclinical Data of its Pancreatic Gene Therapy at DDW 2024
Shots:
- Fractyl highlighted preclinical data of Rejuva pancreatic gene therapy candidate under the title, ‘Single-Dose GLP-1-Based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal and Reduces Hepatic Triglycerides in a Murine Model of Obesity’
- The preclinical data demonstrated a 42% decrease in the liver weight & 67% decrease in the liver triglyceride content vs PBO post 2mos.
- The data also showed a 36% reduction in total cholesterol & a 51% reduction in LDL cholesterol vs PBO post 2mos., suggesting GLP-1 PGTx candidate’s potential of minimizing cardiovascular risk due to increased cholesterol levels. The first GLP-1 PGTx candidate nomination for obesity is expected in H2’24 with further exploration in MASLD/MASH
Ref: Fractyl Health| Image: Fractyl Health
Related News:- The US FDA Grants IDE Approval to Fractyl Health for Initiating Remain-1 Trial of Revita to Treat Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
